V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330005993 | 330007537 | 1.84 | 81 | Curative (C) | 2017-08-17 | 2017-08-25 | Carboplatin + Doxorubicin | N | N | 330011961 | FCR |
| 330005994 | 330002840 | null | 55 | Palliative (P) | 2018-07-04 | 2018-07-16 | AML 19 TRIAL | 02 | N | 330012069 | FEC |
| 330005995 | 330002840 | 1.61 | 32.8 | Palliative (P) | 2018-10-17 | 2018-10-17 | VAC | 02 | N | 330012069 | AZACITIDINE |
| 330005996 | 330002841 | 1.75 | 49 | Palliative (P) | 2016-09-24 | 2016-09-28 | NIVOLUMAB | 02 | N | 330012226 | CAPECITABINE + CARBOPLATIN |
| 330005997 | 330002842 | 1.83 | 67 | null | 2017-05-25 | 2017-05-26 | AML 18 TRIAL | N | N | 330012527 | RUXOLITINIB |
| 330005998 | 330002843 | 1.7 | 95.4 | Curative (C) | 2016-03-07 | 2016-03-18 | CARBOPLATIN + RT | N | N | 330012760 | CARBOPLATIN + DOXORUBICIN |
| 330005999 | 330002844 | 0 | 62.2 | Palliative (P) | 2019-08-24 | 2019-08-24 | Carboplatin + Vinorelbine IV &PO D8 | 02 | N | 330012795 | PAC-E |
| 330006000 | 330002845 | 1.65 | 66 | Curative (C) | 2015-12-16 | 2015-12-16 | CARBOPLATIN + RT | N | N | 330012830 | PACLITAXEL |
| 330006001 | 330007539 | 1.83 | 64.8 | Curative (C) | 2015-07-19 | 2015-07-23 | Capecitabine + Cisplatin + RT | 2 | N | 330012831 | CYTARABINE |
| 330006002 | 330002846 | null | 74 | Palliative (P) | 2018-03-06 | 2018-03-06 | Gemcitabine weekly | 02 | N | 330012847 | CAPECITABINE + STREPTOZOCIN |
| 330006003 | 330002847 | 1.63 | 0 | Palliative (P) | 2016-11-03 | 2017-05-18 | PEMBROLIZUMAB | N | N | 330013056 | METHOTREXATE |
| 330006004 | 330002848 | 0 | 10.4 | Curative (C) | 2013-08-09 | 2013-08-23 | ALL UKALL2011 Ind B Sht Dex (PAsp) | N | N | 330013090 | PEMBROLIZUMAB |
| 330006005 | 330002849 | null | 60.3 | Neo-adjuvant (N) | 2016-07-06 | 2016-07-07 | PEMBROLIZUMAB | null | N | 330013209 | ATG + BUSULFAN + FLUDARABINE |
| 330006006 | 330002849 | 1.66 | 76 | Curative (C) | 2017-10-29 | 2017-11-30 | AML17 TRIAL | N | N | 330013209 | ECX |
| 330006007 | 330002849 | 1.74 | 82.3 | Curative (C) | 2016-12-20 | 2016-12-26 | MITOTANE | Y | N | 330013209 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330006008 | 330011524 | null | 65 | null | 2016-01-12 | 2016-01-12 | BEP 3 day | 02 | N | 330013688 | MITOTANE |
| 330006009 | 330002850 | 1.63 | 80.1 | Disease modification (D) | 2017-02-18 | 2017-03-11 | CISPLATIN + VINORELBINE + RT | N | N | 330014280 | CHLORAMBUCIL + RITUXIMAB |
| 330006010 | 330002850 | 0 | 74.8 | Palliative (P) | 2016-12-28 | 2016-12-29 | IDARUBICIN | 02 | N | 330014280 | ADE |
| 330006011 | 330002850 | null | 73.5 | Neo-adjuvant (N) | 2014-03-21 | 2014-03-21 | Dacarbazine | N | N | 330014280 | CVD (NEUROENDOCRINE) |
| 330006012 | 330002850 | 1.62 | 86.3 | null | null | 2018-01-14 | CARBOPLATIN + EPIRUBICIN + PACLITAXEL | N | N | 330014280 | PEMBROLIZUMAB |
| 330006013 | 330002851 | 1.21 | 58.6 | Palliative (P) | null | 2014-09-02 | Vinblastine | null | null | 330015095 | ADE |
| 330006014 | 330002852 | null | 64.2 | Curative (C) | 2016-06-10 | 2016-06-12 | Bendamustine +/- Prednisolone | Y | N | 330015108 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330006015 | 330002853 | 1.8 | null | Adjuvant (A) | 2019-04-23 | 2019-05-16 | HCX (Cape + Cisp + Tras) - Load | 02 | Y | 330015148 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330006016 | 330002854 | 1.89 | 61.5 | Curative (C) | 2013-04-12 | 2013-04-13 | VAC | N | N | 330015213 | CAV |
| 330006017 | 330002855 | 1.53 | 62.2 | Palliative (P) | 2015-12-30 | 2016-01-05 | AC | N | N | 330015218 | FLUOROURACIL + MITOMYCIN + RT |
| 330006018 | 330002855 | 1.62 | null | Not known (9) | 2017-04-09 | 2017-04-10 | CHOP R - 21 days | 02 | N | 330015218 | MITOTANE |
| 330006019 | 330002855 | null | 65 | Adjuvant (A) | 2017-05-08 | 2017-05-11 | CNS Low Grade Glioma Vinblastine | N | null | 330015218 | AZACITIDINE |
| 330006020 | 330002855 | 1.59 | 46.9 | Palliative (P) | 2016-06-22 | 2016-06-22 | Carboplatin + Doxorubicin | 02 | N | 330015218 | VINCRISTINE |
| 330006021 | 330012300 | 1.63 | null | null | 2015-10-11 | 2015-10-12 | VIDE | N | null | 330015325 | CYCLO + RITUXIMAB + VINCRISTINE |
| 330006022 | 330012300 | 1.59 | 47.2 | Neo-adjuvant (N) | 2016-12-06 | 2016-12-16 | VAI (Ifos 3g/m2) | N | N | 330015325 | ETOPOSIDE + IFOSFAMIDE |
| 330006023 | 330002856 | 1.6 | 6.7 | Palliative (P) | 2014-08-24 | 2014-08-31 | Carboplatin + Docetaxel | 2 | N | 330015434 | CEV |
| 330006024 | 330002856 | 1.78 | 630 | null | 2016-12-15 | 2016-12-15 | Cyclophos + Dex + Lenalidomide | Y | N | 330015434 | CYCLOPHOSPHAMIDE + TOPOTECAN |
| 330006025 | 330002856 | 1.75 | 75.2 | Palliative (P) | 2013-11-30 | 2013-12-19 | CARBOPLATIN + RT | 02 | N | 330015434 | AZACITIDINE |
| 330006026 | 330002856 | 1.8 | 97 | Disease modification (D) | 2014-05-12 | 2014-05-12 | ALL UKALL60+ TRIAL | N | N | 330015434 | CETUXIMAB + CISPLATIN + FU |
| 330006027 | 330002857 | 1.63 | 90.6 | Palliative (P) | 2018-01-02 | 2018-01-03 | Methotrexate Intrathecal (any age) | N | N | 330015569 | IMATINIB |
| 330006028 | 330002857 | null | null | Adjuvant (A) | 2013-07-31 | 2013-07-31 | Cisplatin + Pemetrexed | N | null | 330015569 | CAPECITABINE + OXALIPLATIN |
| 330006029 | 330002857 | 1.59 | 63.2 | Palliative (P) | 2015-04-07 | 2015-04-23 | Everolimus 10mg | N | N | 330015569 | AML17 TRIAL |
| 330006030 | 330002858 | 1.68 | 89.7 | Curative (C) | 2013-02-02 | 2013-02-04 | FCiSt | 02 | N | 330015685 | CHLORAMBUCIL |
| 330006031 | 330002859 | 1.74 | null | Disease modification (D) | 2015-04-11 | 2015-04-21 | BLEOMYCIN + CISPLATIN + VINCRISTINE | null | null | 330015691 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 330006032 | 330002860 | 1.68 | 24.4 | Palliative (P) | 2014-09-11 | 2014-12-23 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 330015697 | OCTREOTIDE |
| 330006033 | 330002861 | 1.59 | 109 | Curative (C) | null | 2013-03-20 | PEMBROLIZUMAB | null | null | 330015753 | CHOP R |
| 330006034 | 330002861 | 0 | 75.7 | Adjuvant (A) | null | 2017-04-14 | AML 18 TRIAL | null | null | 330015753 | ACE (GERM CELL) |
| 330006035 | 330002861 | 1.59 | null | null | 2018-02-10 | 2018-02-17 | CARBOPLATIN + RT | N | null | 330015753 | IPILIMUMAB |
| 330006036 | 330002861 | null | 92 | Palliative (P) | 2014-05-08 | 2014-05-08 | ALL UKALL2011 Ind A Std Dex (PAsp) | N | N | 330015753 | CARBOPLATIN + VINCRISTINE |
| 330006037 | 330002862 | 1.78 | 71 | Curative (C) | 2014-02-07 | 2014-02-28 | CNS HGG Temozolomide +XRT | N | N | 330015913 | TOPOTECAN |
| 330006038 | 330002862 | 1.68 | 90 | Palliative (P) | 2015-09-03 | 2015-09-03 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | N | 330015913 | CVD |
| 330006039 | 330002862 | 1.67 | 0 | Curative (C) | 2016-04-09 | 2016-04-22 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | 330015913 | PEMBROLIZUMAB |
| 330006040 | 330002862 | 1.74 | 85.5 | Palliative (P) | 2018-12-07 | 2018-12-07 | PEMBROLIZUMAB | 02 | null | 330015913 | FLUOROURACIL + MITOMYCIN |
| 330006041 | 330002862 | 1.49 | 0 | Curative (C) | 2017-08-01 | 2018-01-30 | Capecitabine | N | N | 330015913 | CYTARABINE HIGH DOSE |
| 330006042 | 330002863 | null | 58.35 | Palliative (P) | 2014-07-15 | 2014-07-28 | ALL UKALL60+ TRIAL | N | N | 330016127 | EVEROLIMUS |